• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Study Purpose

The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that:

  • - is advanced or metastatic (spread to other parts of the body); - has a certain type of abnormal gene called "BRAF"; and.
  • - has not received prior treatment.
All participants in this study will receive pembrolizumab at the study clinic once every 3 weeks as an intravenous (IV) infusion (given directly into a vein). In addition, half of the participants will take encorafenib and binimetinib orally (by mouth) at home every day. Participants may receive pembrolizumab for up to two years. Those participants taking encorafenib and binimetinib can continue until their melanoma is no longer responding. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Male or female participants ≥ 18 years at the time of informed consent.
  • - Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • - Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, according to the AJCC 8th edition.
  • - Presence of at least 1 measurable lesion as detected by radiological and/or photographic methods according to RECIST v1.1.
  • - ECOG performance status 0 or 1.
  • - Documented evidence of a BRAF V600E or V600K mutation in melanoma tumor tissue as previously determined by either PCR or NGS-based local laboratory assay (eg, US FDA-approved test, CE-marked [European conformity] in vitro diagnostic in EU countries, or equivalent), obtained during the course of normal clinical care, in a CLIA- or similarly certified laboratory.
  • - Submission of adequate tumor tissue (archival or newly obtained; block or slides to the sponsor central laboratory(ies) during the screening period and prior to enrollment (SLI)/randomization (Phase 3).
  • - Have not received prior first-line systemic therapy for metastatic or unresectable locally advanced melanoma.
  • - Adequate bone marrow function, hepatic and renal function.
  • - Capable of giving signed informed consent.
Exclusion Criteria.
  • - Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study (including, but not limited to, a participant who is rapidly progressing or has clinically significant tumor related symptoms, in the judgment of the investigator).
  • - Mucosal or ocular melanoma.
  • - Diagnosis of immunodeficiency or an active autoimmune disease that required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
  • - Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
  • - Unable to swallow, retain, and absorb oral medications.
  • - Impairment of GI function or disease which may significantly alter the absorption of oral study intervention (eg, uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, including malabsorption syndrome secondary to prior GI surgery).
  • - Clinically significant cardiovascular diseases, - History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to enrollment (SLI)/randomization (Phase 3).
Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (ie, massive or sub-massive) deep vein thrombosis or pulmonary emboli.
  • - History or current evidence of RVO or current risk factors for RVO (eg, uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes) - Concurrent neuromuscular disorder that is associated with the potential of elevated CK (eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
  • - Current noninfectious pneumonitis or history of noninfectious pneumonitis requiring steroids, or history of radiation pnuemonitis.
  • - Evidence of HBV or HCV infection.
  • - Known history of a positive test for HIV or known AIDS.
  • - Any active infection requiring systemic therapeutic treatment within 2 weeks prior to enrollment (SLI)/ randomization (Phase 3).
  • - Participants with prior or current symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases.
  • - Concurrent or previous other malignancy within 2 years of study entry, except curatively treated basal or squamous cell skin cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, Bowen's disease and Gleason ≤ 6 prostate cancer.
Participants with a history of other curatively treated cancers must be reviewed with the sponsor or designee prior to entering the study.
  • - Participants who previously received and subsequently discontinued encorafenib and/or binimetinib and/or anti-PD-1/-L1 due to severe toxicity.
  • - For participants in the SLI only: Current use or anticipated need for food or drugs that are known moderate or strong CYP3A4 inhibitors during screening and through the DLT-evaluation period.
  • - Participant has not recovered to Grade ≤ 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before enrollment (SLI)/ randomization (Phase 3).
  • - Receipt of protocol defined medications or treatments outside of required intervals before enrollment (SLI)/randomization (Phase 3): - Previous administration with an investigational drug ≤ 6 months prior to enrollment (SLI)/randomization (Phase 3).
  • - Known sensitivity or contraindication to any component of study intervention (encorafenib, binimetinib and pembrolizumab), or their excipients.
  • - Pregnant, confirmed by a positive β-hCG laboratory test result, or is breastfeeding (lactating).
  • - Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04657991
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Pfizer
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Pfizer CT.gov Call Center
Principal Investigator Affiliation Pfizer
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Mexico, New Zealand, Norway, Poland, Russia, Slovakia, South Africa, Spain, Switzerland, Turkey (Türkiye), Ukraine, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Melanoma
Study Website: View Trial Website
Additional Details

This study will compare the efficacy, safety, and tolerability of encorafenib and binimetinib plus pembrolizumab (Triplet Arm) versus placebo plus pembrolizumab (Control Arm) in participants with metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma. The study will have an open-label safety lead-in (SLI) phase to determine the safety recommend Phase 3 dose (RP3D) and pharmacokinetics (PK) of encorafenib and binimetinib plus pembrolizumab combination therapy prior to initiation of the randomized Phase 3 part of the study. Two dose levels of encorafenib in combination with binimetinib plus pembrolizumab will be explored in parallel. A minimum of 12 evaluable participants will be enrolled per dose level. During the double-blind randomized Phase 3 part of the study, approximately 216 eligible participants will be randomized in a 1:1 ratio to the Triplet Arm (at RP3D determined in the SLI) or Control Arm (approximately 108 participants per arm). Randomization will be stratified by prior systemic adjuvant therapy and stage of disease by AJCC (ED8).

Arms & Interventions

Arms

Experimental: Triplet Arm

Encorafenib and Binimetinib in combination with Pembrolizumab

Active Comparator: Control Arm

Pembrolizumab

Interventions

Drug: - Encorafenib

Encorafenib

Drug: - Binimetinib

Binimetinib

Drug: - Pembrolizumab

Pembrolizumab

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

AdventHealth Orlando Infusion Center, Orlando 4167147, Florida 4155751

Status

Address

AdventHealth Orlando Infusion Center

Orlando 4167147, Florida 4155751, 32804

Orlando 4167147, Florida 4155751

Status

Address

AdventHealth Orlando, Investigational Drug Services

Orlando 4167147, Florida 4155751, 32804

AdventHealth Orlando, Orlando 4167147, Florida 4155751

Status

Address

AdventHealth Orlando

Orlando 4167147, Florida 4155751, 32804

Fairway 4271358, Kansas 4273857

Status

Address

The University of Kansas Clinical Research Center

Fairway 4271358, Kansas 4273857, 66205

Overland Park 4276873, Kansas 4273857

Status

Address

The University of Kansas Cancer Center - Overland Park

Overland Park 4276873, Kansas 4273857, 66210

Westwood 4281639, Kansas 4273857

Status

Address

The University of Kansas Cancer Center, Investigational Drug Services

Westwood 4281639, Kansas 4273857, 66205

The University of Kansas Cancer Center, Westwood 4281639, Kansas 4273857

Status

Address

The University of Kansas Cancer Center

Westwood 4281639, Kansas 4273857, 66205

Massachusetts General Hospital, Boston 4930956, Massachusetts 6254926

Status

Address

Massachusetts General Hospital

Boston 4930956, Massachusetts 6254926, 02114

Boston 4930956, Massachusetts 6254926

Status

Address

Ophthalmic Consultants of Boston Inc (OCB)

Boston 4930956, Massachusetts 6254926, 02114

University of Cincinnati Medical Center, Cincinnati 4508722, Ohio 5165418

Status

Address

University of Cincinnati Medical Center

Cincinnati 4508722, Ohio 5165418, 45219

University of Cincinnati Medical Center, West Chester 4520522, Ohio 5165418

Status

Address

University of Cincinnati Medical Center

West Chester 4520522, Ohio 5165418, 45069

University of Tennessee Medical Center, Knoxville 4634946, Tennessee 4662168

Status

Address

University of Tennessee Medical Center

Knoxville 4634946, Tennessee 4662168, 37920

Sarah Cannon Research Institute, Nashville 4644585, Tennessee 4662168

Status

Address

Sarah Cannon Research Institute

Nashville 4644585, Tennessee 4662168, 37203

Tennessee Oncology, PLLC, Nashville 4644585, Tennessee 4662168

Status

Address

Tennessee Oncology, PLLC

Nashville 4644585, Tennessee 4662168, 37203

International Sites

Instituto Alexander Fleming, CABA, Buenos Aires 3435907, Argentina

Status

Address

Instituto Alexander Fleming

CABA, Buenos Aires 3435907, C1426ANZ

Clinica Viedma S. A, Viedma 3832899, Río Negro Province 3838830, Argentina

Status

Address

Clinica Viedma S. A

Viedma 3832899, Río Negro Province 3838830, 8500

Medizinische Universität Graz, Graz 2778067, Austria

Status

Address

Medizinische Universität Graz

Graz 2778067, , 8036

Cliniques universitaires Saint-Luc, Brussels 2800866, Belgium

Status

Address

Cliniques universitaires Saint-Luc

Brussels 2800866, , 1200

Curitiba 3464975, Paraná 3455077, Brazil

Status

Address

Instituto de Oncologia do Paraná - IOP Matriz Mateus Leme

Curitiba 3464975, Paraná 3455077, 80520-174

Curitiba 3464975, Paraná 3455077, Brazil

Status

Address

Instituto de Oncologia do Paraná - IOP Oncoville

Curitiba 3464975, Paraná 3455077, 82305-100

Rio de Janeiro 3451190, Rio de Janeiro 3451189, Brazil

Status

Address

Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA

Rio de Janeiro 3451190, Rio de Janeiro 3451189, 20220-410

Hospital de Clínicas de Passo Fundo, Passo Fundo 3454857, Rio Grande do Sul 3451133, Brazil

Status

Address

Hospital de Clínicas de Passo Fundo

Passo Fundo 3454857, Rio Grande do Sul 3451133, 99010-260

Hospital de Clinicas de Porto Alegre, Porto Alegre 3452925, Rio Grande do Sul 3451133, Brazil

Status

Address

Hospital de Clinicas de Porto Alegre

Porto Alegre 3452925, Rio Grande do Sul 3451133, 90035-903

Barretos 3470451, São Paulo 3448433, Brazil

Status

Address

Fundação Pio XII - Hospital de Câncer de Barretos

Barretos 3470451, São Paulo 3448433, 14784-400

São Paulo 3448439, Brazil

Status

Address

Hospital Sírio-Libanês - Unidade Bela Vista

São Paulo 3448439, , 01308-050

Complex Oncology Center - Plovdiv EOOD, Plovdiv 728193, Bulgaria

Status

Address

Complex Oncology Center - Plovdiv EOOD

Plovdiv 728193, , 4004

Medical Center Nadezhda Clinical EOOD, Sofia 727011, Bulgaria

Status

Address

Medical Center Nadezhda Clinical EOOD

Sofia 727011, , 1373

Sofia 727011, Bulgaria

Status

Address

Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda EAD

Sofia 727011, , 1407

Umhato Ead, Sofia 727011, Bulgaria

Status

Address

Umhato Ead

Sofia 727011, , 1756

CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi 5921225, Quebec 6115047, Canada

Status

Address

CIUSSS du Saguenay-Lac-Saint-Jean

Chicoutimi 5921225, Quebec 6115047, G7H 5H6

Olomouc University Hospital, Olomouc 3069011, Olomoucký kraj 3339542, Czechia

Status

Address

Olomouc University Hospital

Olomouc 3069011, Olomoucký kraj 3339542, 779 00

Fakultni nemocnice Ostrava, Ostrava-Poruba, Czechia

Status

Address

Fakultni nemocnice Ostrava

Ostrava-Poruba, , 708 52

Fakultni nemocnice Bulovka, Praha 8-Liben, Czechia

Status

Address

Fakultni nemocnice Bulovka

Praha 8-Liben, , 180 81

Tampereen yliopistollinen sairaala, Tampere 634963, Pirkanmaa 830704, Finland

Status

Address

Tampereen yliopistollinen sairaala

Tampere 634963, Pirkanmaa 830704, 33520

Helsinki 658225, Finland

Status

Address

Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus)

Helsinki 658225, , 00029

CHU d'Amiens - Hôpital Nord, Amiens 3037854, France

Status

Address

CHU d'Amiens - Hôpital Nord

Amiens 3037854, , 80054

CHU Grenoble Alpes, La Tronche 3006131, France

Status

Address

CHU Grenoble Alpes

La Tronche 3006131, , 38700

Hôpital Lyon Sud, Pierre-Bénite 2987314, France

Status

Address

Hôpital Lyon Sud

Pierre-Bénite 2987314, , 69310

CHU de Poitiers, Poitiers 2986495, France

Status

Address

CHU de Poitiers

Poitiers 2986495, , 86000

Universitaetsklinikum Tuebingen, Tübingen 2820860, Baden-Wurttemberg 2953481, Germany

Status

Address

Universitaetsklinikum Tuebingen

Tübingen 2820860, Baden-Wurttemberg 2953481, 72076

München 2867713, Bavaria 2951839, Germany

Status

Address

Klinik und Poliklinik für Dermatologie und Allergologie

München 2867713, Bavaria 2951839, 80337

Universitätsklinikum Bonn, Bonn 2946447, North Rhine-Westphalia 2861876, Germany

Status

Address

Universitätsklinikum Bonn

Bonn 2946447, North Rhine-Westphalia 2861876, 53127

Johannes Wesling Klinikum Minden, Minden 2871039, North Rhine-Westphalia 2861876, Germany

Status

Address

Johannes Wesling Klinikum Minden

Minden 2871039, North Rhine-Westphalia 2861876, 32429

Mainz 2874225, Rhineland-Palatinate 2847618, Germany

Status

Address

Universitätsmedizin Johannes Gutenberg Universität Mainz

Mainz 2874225, Rhineland-Palatinate 2847618, 55131

Dresden 2935022, Saxony 2842566, Germany

Status

Address

Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden

Dresden 2935022, Saxony 2842566, 01307

Universitätsklinikum Leipzig, Leipzig 2879139, Saxony 2842566, Germany

Status

Address

Universitätsklinikum Leipzig

Leipzig 2879139, Saxony 2842566, 04103

Kiel 2891122, Schleswig-Holstein 2838632, Germany

Status

Address

Universitaetsklinikum Schleswig-Holstein Campus Kiel

Kiel 2891122, Schleswig-Holstein 2838632, 24105

Universitätsklinikum Schleswig-Holstein, Lübeck 2875601, Schleswig-Holstein 2838632, Germany

Status

Address

Universitätsklinikum Schleswig-Holstein

Lübeck 2875601, Schleswig-Holstein 2838632, 23538

SRH Wald-Klinikum Gera, Gera 2921232, Thuringia 2822542, Germany

Status

Address

SRH Wald-Klinikum Gera

Gera 2921232, Thuringia 2822542, 07548

Berlin 2950159, Germany

Status

Address

Charité Universitaetsmedizin Berlin - Campus Mitte

Berlin 2950159, , 10117

HELIOS Klinikum Erfurt, Erfurt 2929670, Germany

Status

Address

HELIOS Klinikum Erfurt

Erfurt 2929670, , 99089

Universitätsklinikum Essen (AöR), Essen 2928810, Germany

Status

Address

Universitätsklinikum Essen (AöR)

Essen 2928810, , 45147

Halle 2911522, Germany

Status

Address

Universitaetsklinikum Halle - Universitaetsklinik und Poliklinik fuer Dermatologie und Venerologie

Halle 2911522, , 06120

Universitaetsklinikum Hamburg-Eppendorf, Hamburg 2911298, Germany

Status

Address

Universitaetsklinikum Hamburg-Eppendorf

Hamburg 2911298, , 20246

Medizinische Hochschule Hannover, Hanover 2910831, Germany

Status

Address

Medizinische Hochschule Hannover

Hanover 2910831, , 30625

Universitätsklinikum Heidelberg, Heidelberg 2907911, Germany

Status

Address

Universitätsklinikum Heidelberg

Heidelberg 2907911, , 69120

University Hospital Muenster, Münster 2867543, Germany

Status

Address

University Hospital Muenster

Münster 2867543, , 48149

Fachklinik Hornheide, Münster 2867543, Germany

Status

Address

Fachklinik Hornheide

Münster 2867543, , 48157

Klinikum Nürnberg Nord, Nuremberg 2861650, Germany

Status

Address

Klinikum Nürnberg Nord

Nuremberg 2861650, , 90419

Universitätsklinikum Regensburg, Regensburg 2849483, Germany

Status

Address

Universitätsklinikum Regensburg

Regensburg 2849483, , 93053

General Hospital of Athens "Laiko", Athens 264371, Attikí, Greece

Status

Address

General Hospital of Athens "Laiko"

Athens 264371, Attikí, 11527

Laiko Hospital, Athens 264371, Attikí, Greece

Status

Address

Laiko Hospital

Athens 264371, Attikí, 11527

Pécsi Tudományegyetem Klinikai Központ, Pécs 3046526, Baranya 3055399, Hungary

Status

Address

Pécsi Tudományegyetem Klinikai Központ

Pécs 3046526, Baranya 3055399, 7632

Szolnok 715126, Jász-Nagykun-Szolnok 719637, Hungary

Status

Address

Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház

Szolnok 715126, Jász-Nagykun-Szolnok 719637, 5004

Semmelweis Egyetem, Budapest 3054643, Hungary

Status

Address

Semmelweis Egyetem

Budapest 3054643, , 1085

Orszagos Onkologiai Intezet, Budapest 3054643, Hungary

Status

Address

Orszagos Onkologiai Intezet

Budapest 3054643, , 1122

Debreceni Egyetem Klinikai Kozpont, Debrecen 721472, Hungary

Status

Address

Debreceni Egyetem Klinikai Kozpont

Debrecen 721472, , 4032

Szent-Gyorgyi Albert Klinikai Kozpont, Szeged 715429, Hungary

Status

Address

Szent-Gyorgyi Albert Klinikai Kozpont

Szeged 715429, , 6720

Soroka University Medical Center, Beersheba 295530, Israel

Status

Address

Soroka University Medical Center

Beersheba 295530, , 8410101

Jerusalem 281184, Israel

Status

Address

Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem

Jerusalem 281184, , 9112001

Udine 3165072, Friuli Venezia Giulia 3176525, Italy

Status

Address

Azienda Sanitaria Universitaria Friuli Centrale

Udine 3165072, Friuli Venezia Giulia 3176525, 33100

Milan 6951411, MI, Italy

Status

Address

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan 6951411, MI, 20133

Roma 8957247, RM, Italy

Status

Address

Istituto Dermopatico dell'Immacolata (IDI-IRCCS)

Roma 8957247, RM, 00167

A.O.U.S. Policlinico "Le Scotte", Siena 3166548, SI, Italy

Status

Address

A.O.U.S. Policlinico "Le Scotte"

Siena 3166548, SI, 53100

Candiolo 3180861, Torino, Italy

Status

Address

Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia

Candiolo 3180861, Torino, 10060

Istituto Tumori Giovanni Paolo II, Bari 3182351, Italy

Status

Address

Istituto Tumori Giovanni Paolo II

Bari 3182351, , 70124

IRCCS Ospedale Policlinico San Martino, Genova 8969657, Italy

Status

Address

IRCCS Ospedale Policlinico San Martino

Genova 8969657, , 16132

Istituto Europeo di Oncologia IRCCS, Milan 6951411, Italy

Status

Address

Istituto Europeo di Oncologia IRCCS

Milan 6951411, , 20141

Napoli 9031661, Italy

Status

Address

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Napoli 9031661, , 80131

Istituto Oncologico Veneto IOV - IRCCS, Padua 3171728, Italy

Status

Address

Istituto Oncologico Veneto IOV - IRCCS

Padua 3171728, , 35128

Perugia 3171180, Italy

Status

Address

AO di Perugia - Ospedale S. Maria della Misericordia, S.C Oncologia Medica

Perugia 3171180, , 06132

Istituto Nazionale Tumori Regina Elena, Roma 8957247, Italy

Status

Address

Istituto Nazionale Tumori Regina Elena

Roma 8957247, , 00144

Preparaciones Oncológicas S.C., León 3998655, Guanajuato 4005267, Mexico

Status

Address

Preparaciones Oncológicas S.C.

León 3998655, Guanajuato 4005267, 37178

ONCARE Viaducto Nápoles, Benito Juárez 6957079, Mexico City 3527646, Mexico

Status

Address

ONCARE Viaducto Nápoles

Benito Juárez 6957079, Mexico City 3527646, 03810

I Can Oncology Center S.A. de C.V., Monterrey 3995465, Nuevo León 3522542, Mexico

Status

Address

I Can Oncology Center S.A. de C.V.

Monterrey 3995465, Nuevo León 3522542, 64710

BRCR Global Mexico - CDMX, Mexico City 3530597, Mexico

Status

Address

BRCR Global Mexico - CDMX

Mexico City 3530597, , 01120

El Cielo Medical Center RSB, S.C, Puebla City 3521081, Mexico

Status

Address

El Cielo Medical Center RSB, S.C

Puebla City 3521081, , 72160

Palmerston North Hospital, Palmerston North 2185018, Manawatu, New Zealand

Status

Address

Palmerston North Hospital

Palmerston North 2185018, Manawatu, 4414

Oslo 3143244, Norway

Status

Address

Oslo universitetssykehus, Radiumhospitalet

Oslo 3143244, , 0379

Krakow 3094802, Poland

Status

Address

Jagiellońskie Centrum Innowacji Sp. z o .o.

Krakow 3094802, , 30-348

Poznan 3088171, Poland

Status

Address

Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu

Poznan 3088171, , 60-780

Warsaw 756135, Poland

Status

Address

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy

Warsaw 756135, , 02-781

Pushkin 504003, Sankt-Peterburg 536203, Russia

Status

Address

Private Medical Institution "Euromedservice"

Pushkin 504003, Sankt-Peterburg 536203, 196603

Ars Medika Center, LLC, Kaliningrad 554234, Russia

Status

Address

Ars Medika Center, LLC

Kaliningrad 554234, ,

Omsk 1496153, Russia

Status

Address

BIH of Omsk Region "Clinical Oncological Dispensary"

Omsk 1496153, , 644046

Eurocityclinic LLC, Saint Petersburg 498817, Russia

Status

Address

Eurocityclinic LLC

Saint Petersburg 498817, , 197022

Onkologicky ustav sv. Alzbety, s.r.o., Bratislava 3060972, Slovakia

Status

Address

Onkologicky ustav sv. Alzbety, s.r.o.

Bratislava 3060972, , 812 50

Narodny onkologicky ustav, Bratislava 3060972, Slovakia

Status

Address

Narodny onkologicky ustav

Bratislava 3060972, , 833 10

Vychodoslovensky onkologicky ustav, a.s., Košice 724443, Slovakia

Status

Address

Vychodoslovensky onkologicky ustav, a.s.

Košice 724443, , 04191

Nemocnica na okraji mesta, n.o., Partizánske 3058268, Slovakia

Status

Address

Nemocnica na okraji mesta, n.o.

Partizánske 3058268, , 95801

POKO Poprad, s.r.o., Poprad 723846, Slovakia

Status

Address

POKO Poprad, s.r.o.

Poprad 723846, , 058 01

WCR Office, Johannesburg 993800, Gauteng 1085594, South Africa

Status

Address

WCR Office

Johannesburg 993800, Gauteng 1085594, 2193

Wits Clinical Research, Johannesburg 993800, Gauteng 1085594, South Africa

Status

Address

Wits Clinical Research

Johannesburg 993800, Gauteng 1085594, 2193

Sandton Oncology Medical Group (Pty) Ltd, Johannesburg 993800, Gauteng 1085594, South Africa

Status

Address

Sandton Oncology Medical Group (Pty) Ltd

Johannesburg 993800, Gauteng 1085594, 2196

Drs Alberts, Bouwer and Jordaan Inc., Pretoria 964137, Gauteng 1085594, South Africa

Status

Address

Drs Alberts, Bouwer and Jordaan Inc.

Pretoria 964137, Gauteng 1085594, 0081

Badalona 3129028, Barcelona, Spain

Status

Address

ICO-Badalona Hospital Germans Trias i Pujol

Badalona 3129028, Barcelona, 08916

Santander 3109718, Cantabria 3336898, Spain

Status

Address

Hospital Universitario Marqués de Valdecilla

Santander 3109718, Cantabria 3336898, 39008

Majadahonda 3117667, Madrid 3117732, Spain

Status

Address

Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda 3117667, Madrid 3117732, 28222

El Palmar 2518294, Murcia 2513413, Spain

Status

Address

Hospital Clinico Universitario Virgen de la Arrixaca

El Palmar 2518294, Murcia 2513413, 30120

CHUAC-Hospital Teresa Herrera, A Coruña 3119841, Spain

Status

Address

CHUAC-Hospital Teresa Herrera

A Coruña 3119841, , 15006

Barcelona 3128760, Spain

Status

Address

Hospital Universitari Vall D'Hebron, Servicio de Oncología Médica

Barcelona 3128760, , 08035

Hospital Clinic Barcelona, Barcelona 3128760, Spain

Status

Address

Hospital Clinic Barcelona

Barcelona 3128760, , 08036

Hospital de la Santa Creu i Sant Pau, Barcelona 3128760, Spain

Status

Address

Hospital de la Santa Creu i Sant Pau

Barcelona 3128760, , 08041

Hospital Universitario Reina Sofía, Córdoba 2519240, Spain

Status

Address

Hospital Universitario Reina Sofía

Córdoba 2519240, , 14004

Complejo Hospitalario de Jaen, Jaén 2516395, Spain

Status

Address

Complejo Hospitalario de Jaen

Jaén 2516395, , 23007

Hospital Universitario Arnau de Vilanova, Lleida 3118514, Spain

Status

Address

Hospital Universitario Arnau de Vilanova

Lleida 3118514, , 25198

Hospital Universitario Ramón y Cajal, Madrid 3117735, Spain

Status

Address

Hospital Universitario Ramón y Cajal

Madrid 3117735, , 28034

Málaga 2514256, Spain

Status

Address

Hospital Regional Universitario de Malaga - Hospital Civil

Málaga 2514256, , 29011

Hospital Universitario Virgen Macarena, Seville 2510911, Spain

Status

Address

Hospital Universitario Virgen Macarena

Seville 2510911, , 41009

Hospital Universitario Virgen del Rocio, Seville 2510911, Spain

Status

Address

Hospital Universitario Virgen del Rocio

Seville 2510911, , 41013

Valencia 2509954, Spain

Status

Address

Fundacion Instituto Valenciano de Oncologia

Valencia 2509954, , 46009

Hospital Universitario Miguel Servet, Zaragoza 3104324, Spain

Status

Address

Hospital Universitario Miguel Servet

Zaragoza 3104324, , 50009

UniversitätsSpital Zürich, Zürich Flughafen, Switzerland

Status

Address

UniversitätsSpital Zürich

Zürich Flughafen, , 8058

Istanbul 745044, İ̇stanbul, Turkey (Türkiye)

Status

Address

Istanbul University Cerrahpasa Medical Faculty Hospital

Istanbul 745044, İ̇stanbul, 34098

Istanbul 745044, İ̇stanbul, Turkey (Türkiye)

Status

Address

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi

Istanbul 745044, İ̇stanbul, 34722

Memorial Ankara Hastanesi, Ankara 323786, Turkey (Türkiye)

Status

Address

Memorial Ankara Hastanesi

Ankara 323786, , 06520

CNI KRC "Regional Cardiology Centre", Kharkiv 706483, Ukraine

Status

Address

CNI KRC "Regional Cardiology Centre"

Kharkiv 706483, , 61166

National Cancer Institute, Kyiv 703448, Ukraine

Status

Address

National Cancer Institute

Kyiv 703448, , 03022

Lviv 702550, Ukraine

Status

Address

Communal Noncommercial Enterprise of Lviv Regional Council "Lviv Oncological Regional Therapeutical

Lviv 702550, , 79031

M. Kharkiv, Ukraine

Status

Address

Derzhavna ustanova Instytut zahalnoi ta nevidkladnoi khirurhii im.V.T.Zaitseva Natsionalnoi akademii

M. Kharkiv, , 61103

London 2643743, United Kingdom

Status

Address

St. Bartholomew's Hospital, Barts Health NHS Trust

London 2643743, , EC1A 7BE

Swansea 2636432, United Kingdom

Status

Address

The South West Wales Cancer Institute, Swansea Bay University Health Board

Swansea 2636432, , SA2 8QA

Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact